PureTech Health (LON:PRTC) Stock Passes Below 50-Day Moving Average – Should You Sell?

PureTech Health plc (LON:PRTC) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 129.42 and traded as low as GBX 122. PureTech Health shares last traded at GBX 122.58, with a volume of 287,786 shares traded.

Analysts Set New Price Targets

Separately, Peel Hunt restated a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a research note on Monday, December 8th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of GBX 508.

PureTech Health Stock Performance

The company has a 50-day moving average price of GBX 129.37 and a two-hundred day moving average price of GBX 127.52. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The stock has a market capitalization of £298.25 million, a P/E ratio of 7.26 and a beta of 1.02.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.